Friday, Jul 24, 2026 The claims desk. Receipts included. POWERED BY LENZ ↗
IsThis

HEALTH

The Claim

Pfizer Inc. listed hantavirus pulmonary syndrome as a potential adverse event of special interest (AESI) or possible side effect in its COVID-19 vaccine safety monitoring documents for the BNT162b2 (Comirnaty) vaccine.

Verified by Lenz ·

The Short Version

Pfizer’s safety-monitoring materials did include hantavirus pulmonary syndrome on an AESI-style surveillance list for BNT162b2. That supports the claim’s core factual point. But this does not show Pfizer identified it as a confirmed or likely side effect, and official labeling and regulator product information do not list it as an established adverse reaction.

Caveats

  • An AESI entry is a monitoring signal category, not proof that the vaccine causes that condition.
  • Pfizer’s patient-facing safety information and major regulators’ product information do not list hantavirus pulmonary syndrome as a known or labeled side effect.
  • The document appears to use broad surveillance terminology; inclusion may reflect precautionary term capture rather than a specific mechanistic concern about Comirnaty.

The Receipts

  1. Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years

    CDC (Centers for Disease Control and Prevention)

  2. Patient Package Insert - COMIRNATY (COVID-19 Vaccine, mRNA)

    Pfizer

  3. Side Effects & Safety | COMIRNATY® (COVID-19 Vaccine, mRNA)

    COMIRNATY Official Website

  4. WHO SAGE Recommendation on the Use of the Pfizer BioNTech COVID-19 Vaccine

    World Health Organization (WHO)

  5. COMIRNATY - Product Information

    European Medicines Agency (EMA)

  6. Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine

    PubMed Central (NIH)

  7. 5.3.6 cumulative analysis of post-authorization adverse event ...

    Colorado General Assembly

  8. COVID-19 Vaccine - Pfizer-BioNTech (Comirnaty)

    Health Canada

  9. Myocarditis and Pericarditis After mRNA COVID-19 Vaccination

    CDC

  10. Adverse events of special interest following the use of BNT162b2 in adolescents: a case series from the voluntary reporting system in Hong Kong

    PubMed Central (PMC)

+ 10 more sources — see the full list on Lenz

Filed Under

BNT162b2 (Comirnaty)Hantavirus Pulmonary SyndromePfizer Inc.

More Fact Checks